



November 15, 2022

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer, President, and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Investor Relations
Akihiro Nakano
(TEL. 03-6214-3600)

GNI Group invests in joint venture in Shanghai, China to expand its aesthetics business

November 15, 2022 – GNI Group Ltd., (TSE Growth Board: 2160) is pleased to announce that the Group, through its subsidiary Continent Pharmaceuticals U.S., Inc., the Group has invested RMB 9.5 million for 20% ownership of Shanghai Ruixing Medical Equipment Co., Ltd. (Ruixing Medical below), a newly formed joint venture in Shanghai, China. Ruixing Medical's expertise and focus is dermatology / aesthetic applications, which will leverage the Group's proprietary biomaterials technology. The JV's impact is minor and will be included in Medical Device Segment of the Group's reported financials.

This JV is a part of our previously announced strategy to consolidate our various biomaterials businesses, including the joint venture with EPS Group in Japan (please refer to [our announcement on October 7, 2022](#)), under a single Medical Device Segment to achieve faster growth and international expansion.

The Group continues to leverage and rigorously manage its cost-effective clinical development and early commercialization platform in China. Before embarking on costly global development, new products and applications are developed, tested, and marketed in China. In aesthetics field, proprietary biomaterial will first be used in dermal filler applications, which are expected to be a USD14.4 billion market globally by 2031 according to Allied Market Research:

<https://www.globenewswire.com/en/news-release/2022/10/25/2540897/0/en/Global-Dermal-Filler-Market-Is-Expected-to-Reach-14-4-Billion-by-2031-Says-AMR.html>).

Further expansion of biomaterial applications to areas other than orthopedics, in which one of our core subsidiaries Berkley Advanced Biomaterials excels, will prepare the Group for a stronger growth in the aftermath of the pandemic, while serving as a solid cash flow supplement to our core strength in the pharmaceutical industry.

About GNI Group, Inc.:

GNI Group is a global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below

<https://www.gnipharma.com/>



This material contains statements concerning the current plans, expectations, and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operating activities, business performance, events, or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Group, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of GNI Group must be based on the information contained in the preliminary offering circular issued or to be issued by GNI Group in connection with any such offer and not on the contents hereof.